Intra-Cellular Therapies, Inc. (ITCI) reported second-quarter 2024 loss of 16 cents per share, narrower than the Zacks Consensus Estimate of a loss of 18 cents, primarily due to higher product sales. The company had incurred a loss of 45 cents per share in the year-ago quarter. Total revenues, comprising product sales and grant revenues, came in at $161.4 million, up 46% year over year. The top line beat the Zacks Consensus Estimate of $158 million. Quarter in Detail Caplyta, the only approved drug in Intra ...